Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN.

Clin Cancer Res. 2001 Apr;7(4):839-45.

2.

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Ohgaki H, Kleihues P.

J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. Review.

PMID:
15977639
3.

Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

Cairncross G, Jenkins R.

Cancer J. 2008 Nov-Dec;14(6):352-7. doi: 10.1097/PPO.0b013e31818d8178. Review.

PMID:
19060598
4.

[Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].

Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):595-604. doi: 10.1016/j.neurol.2008.04.002. Epub 2008 May 21. Review. French.

PMID:
18565359
5.

Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.

Sonabend AM, Lesniak MS.

Expert Rev Neurother. 2005 Nov;5(6 Suppl):S25-32. Review.

PMID:
16274268
6.
7.

[Place of chemotherapy and radiotherapy in the management of oligodendrogliomas].

Cartalat-Carel S, Chinot O, Honnorat J.

Neurochirurgie. 2005 Sep;51(3-4 Pt 2):379-92. Review. French.

PMID:
16292180
8.

Oligodendrogliomas: molecular biology and treatment.

Bromberg JE, van den Bent MJ.

Oncologist. 2009 Feb;14(2):155-63. doi: 10.1634/theoncologist.2008-0248. Epub 2009 Jan 31. Review.

9.

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Reifenberger G, Louis DN.

J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26. Review.

PMID:
12578221
10.

Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC.

J Clin Oncol. 2006 Mar 10;24(8):1246-52. Review.

PMID:
16525179
11.

Oligodendroglioma: pathology and molecular biology.

Engelhard HH, Stelea A, Cochran EJ.

Surg Neurol. 2002 Aug;58(2):111-7; discussion 117. Review.

PMID:
12453646
12.

[The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].

Kros JM.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1379-85. Review. Dutch.

PMID:
15997690
13.

Diagnosis and management of oligodendroglioma.

van den Bent MJ.

Semin Oncol. 2004 Oct;31(5):645-52. Review.

PMID:
15497117
14.

New treatment paradigm for patients with anaplastic oligodendroglial tumors.

Polivka J Jr, Polivka J, Rohan V, Topolcan O.

Anticancer Res. 2014 Apr;34(4):1587-94. Review.

PMID:
24692686
15.

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

Fortin D, Cairncross GJ, Hammond RR.

Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191. Review.

PMID:
10598694
16.

Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications.

Smith JS, Jenkins RB.

Front Biosci. 2000 Jan 1;5:D213-31. Review.

PMID:
10702383
17.

From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation.

Koeller KK, Rushing EJ.

Radiographics. 2005 Nov-Dec;25(6):1669-88. Review.

PMID:
16284142
18.

Bony metastases of anaplastic oligodendroglioma respond to temozolomide.

Morrison T, Bilbao JM, Yang G, Perry JR.

Can J Neurol Sci. 2004 Feb;31(1):102-8. Review.

PMID:
15038479
19.

Clinical management of grade III oligodendroglioma.

Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A.

Cancer Manag Res. 2015 Jul 27;7:213-23. doi: 10.2147/CMAR.S56975. eCollection 2015. Review.

20.

[New treatments in brain tumors].

Graus F.

Neurologia. 1999 Dec;14 Suppl 6:21-5. Review. Spanish.

PMID:
10659602

Supplemental Content

Support Center